Es gab 50 kürzliche Insider-Transaktionen für Calithera Biosciences, Inc. (CALA), darunter 25 Käufe und 25 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $1.11M und die gesamten Insider-Verkäufe auf $80.46M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Takeda Pharmaceutical Co Ltd, Pakianathan Deepika, Molineaux Susan. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — CALA
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2023-04-17 |
Takeda Pharmaceutical Co Ltd |
Officer |
Sonstige (Verkauf) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2023-01-27 |
Pakianathan Deepika |
Director |
Informierter Verkauf |
1,172 |
$0.39 |
$452.16 |
- |
| 2023-01-23 |
Molineaux Susan |
President & CEO |
RSU-Steuereinbehalt |
526 |
$0.45 |
$234.65 |
27,859 |
| 2023-01-23 |
Wong Stephanie |
See Remarks |
RSU-Steuereinbehalt |
317 |
$0.45 |
$141.41 |
6,287 |
| 2023-01-23 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Steuereinbehalt |
279 |
$0.45 |
$124.46 |
8,467 |
| 2023-01-23 |
Molineaux Christopher |
Sr. VP, Development |
RSU-Steuereinbehalt |
217 |
$0.45 |
$96.80 |
27,859 |
| 2023-01-23 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Steuereinbehalt |
79 |
$0.45 |
$35.24 |
3,539 |
| 2022-07-01 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
Sonstige (Verkauf) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2022-07-01 |
Takeda Ventures, Inc. |
Director |
Sonstige (Verkauf) |
1,000,000 |
- |
- |
- |
| 2022-06-01 |
Pakianathan Deepika |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wolff Henry Ward |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Garland J. Scott |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Agarwal Sunil |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wise Blake |
Director |
RSU-Zuteilung |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Orford Keith |
Director |
RSU-Zuteilung |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Jones Suzy |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-01-25 |
Molineaux Susan |
President & CEO |
RSU-Zuteilung |
597,475 |
$0.44 |
$262.89K |
597,475 |
| 2022-01-25 |
Wong Stephanie |
See Remarks |
RSU-Zuteilung |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-25 |
Ray Sumita |
See Remarks |
RSU-Zuteilung |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Zuteilung |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Molineaux Christopher |
Sr. VP, Development |
RSU-Zuteilung |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Orford Keith |
Director |
RSU-Zuteilung |
40,000 |
$0.44 |
$17.6K |
40,000 |
| 2022-01-25 |
Parlati Francesco |
Sr. VP, Research |
RSU-Zuteilung |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Zuteilung |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-21 |
Wong Stephanie |
See Remarks |
RSU-Steuereinbehalt |
5,586 |
$0.49 |
$2.75K |
132,085 |
| 2022-01-21 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Steuereinbehalt |
4,794 |
$0.49 |
$2.36K |
172,434 |
| 2022-01-21 |
Parlati Francesco |
Sr. VP, Research |
RSU-Steuereinbehalt |
4,794 |
$0.49 |
$2.36K |
140,998 |
| 2022-01-21 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Steuereinbehalt |
666 |
$0.49 |
$327.34 |
67,369 |
| 2022-01-04 |
Wong Stephanie |
See Remarks |
RSU-Steuereinbehalt |
18,077 |
$0.66 |
$11.94K |
137,671 |
| 2022-01-04 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Steuereinbehalt |
18,077 |
$0.66 |
$11.94K |
177,228 |
| 2022-01-04 |
Parlati Francesco |
Sr. VP, Research |
RSU-Steuereinbehalt |
18,077 |
$0.66 |
$11.94K |
145,792 |
| 2022-01-04 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Steuereinbehalt |
3,855 |
$0.66 |
$2.55K |
68,035 |
| 2021-11-11 |
Orford Keith |
Director |
Informierter Verkauf |
48,190 |
$0.88 |
$42.41K |
66,094 |
| 2021-11-10 |
Molineaux Susan |
President & CEO |
Informierter Kauf |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Drachman Jonathan G |
Director |
Informierter Kauf |
200,000 |
$0.86 |
$171.9K |
200,000 |
| 2021-11-10 |
Molineaux Christopher |
Sr. VP, Development |
Informierter Kauf |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Orford Keith |
Director |
Informierter Verkauf |
30,000 |
$0.86 |
$25.7K |
114,284 |
| 2021-11-09 |
Orford Keith |
Director |
Informierter Verkauf |
51,810 |
$0.84 |
$43.52K |
144,284 |
| 2021-11-08 |
Wong Stephanie |
See Remarks |
RSU-Steuereinbehalt |
15,566 |
$0.87 |
$13.54K |
155,748 |
| 2021-11-08 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Steuereinbehalt |
15,566 |
$0.87 |
$13.54K |
195,305 |
| 2021-11-08 |
Parlati Francesco |
Sr. VP, Research |
RSU-Steuereinbehalt |
15,566 |
$0.87 |
$13.54K |
163,869 |
| 2021-11-08 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Steuereinbehalt |
3,077 |
$0.87 |
$2.68K |
69,390 |
| 2021-11-05 |
Wong Stephanie |
See Remarks |
RSU-Zuteilung |
30,000 |
- |
- |
171,314 |
| 2021-11-05 |
Ray Sumita |
See Remarks |
RSU-Zuteilung |
12,000 |
- |
- |
105,000 |
| 2021-11-05 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU-Zuteilung |
30,000 |
- |
- |
210,871 |
| 2021-11-05 |
Molineaux Christopher |
Sr. VP, Development |
RSU-Zuteilung |
12,000 |
- |
- |
102,500 |
| 2021-11-05 |
Orford Keith |
Director |
RSU-Zuteilung |
30,000 |
- |
- |
196,094 |
| 2021-11-05 |
Parlati Francesco |
Sr. VP, Research |
RSU-Zuteilung |
30,000 |
- |
- |
179,435 |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
Veräußerung |
33,375 |
$2.98 |
$99.46K |
- |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
RSU-Zuteilung |
12,000 |
- |
- |
72,467 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
